Valuation: Gabather AB

Market Cap 17.22M 1.75M 1.53M 1.44M 1.31M 2.46M 168M 2.46M 6.63M 85.46M 6.57M 6.43M 277M P/E 2024
-1.07x
P/E 2025 -1.13x
Enterprise Value 14.07M 1.43M 1.25M 1.17M 1.07M 2.01M 137M 2.01M 5.42M 69.86M 5.37M 5.25M 227M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
90.95%
Yield 2024 *
-
Yield 2025 -
1 day-1.40%
1 week-6.62%
Current month-21.67%
1 month-10.76%
3 months-25.40%
6 months-42.91%
Current year+2.92%
1 week 0.02
Extreme 0.0248
0.03
1 month 0.02
Extreme 0.0248
0.04
Current year 0.02
Extreme 0.023
0.1
1 year 0.02
Extreme 0.023
0.1
3 years 0.02
Extreme 0.023
4.2
5 years 0.02
Extreme 0.023
6.55
10 years 0.02
Extreme 0.023
61.6
Manager TitleAgeSince
Chief Executive Officer - 2018-09-30
Chief Operating Officer - 2017-12-31
Chief Tech/Sci/R&D Officer - 2017-12-31
Director TitleAgeSince
Director/Board Member - 2014-08-31
Director/Board Member 60 2014-11-02
Chairman - 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.40%-6.62%-20.34%-98.84% 1.77M
+4.98%+11.06%+54.45%+109.45% 70.88B
-0.39%+1.66%+38.84%+78.01% 62.49B
+5.26%+12.77%+40.29%+26.34% 26.34B
+0.83%-6.50%-16.41%+374.14% 26.21B
+2.02%+1.31%+1.85%-9.77% 24.13B
0.00%+8.03%+25.03%-13.74% 20.72B
-2.54%-10.16%+149.64%+313.93% 15.69B
-1.95%+1.96%+42.69%+166.02% 14.46B
-5.32%-3.70%-10.53%+808.60% 14.24B
Average +0.15%+1.23%+30.55%+175.41% 27.52B
Weighted average by Cap. +1.43%+2.90%+37.42%+150.65%

Financials

2024 2025
Net sales - -
Net income -7.75M -788K -687K -647K -590K -1.11M -75.51M -1.11M -2.99M -38.48M -2.96M -2.89M -125M -4.65M -473K -412K -388K -354K -664K -45.31M -664K -1.79M -23.09M -1.78M -1.74M -74.97M
Net Debt -878K -89.25K -77.84K -73.28K -66.77K -125K -8.55M -125K -338K -4.36M -335K -328K -14.15M -3.14M -320K -279K -262K -239K -448K -30.61M -449K -1.21M -15.6M -1.2M -1.17M -50.65M
Logo Gabather AB
Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.
Employees
2
Date Price Change Volume
26-09-21 SEK 0.0282 -1.40% 692,727
26-09-18 SEK 0.0286 +6.72% 2,474,363
26-09-17 SEK 0.0268 +0.75% 1,332,452
26-09-16 SEK 0.0266 -2.92% 1,045,106
26-09-15 SEK 0.0274 -8.67% 2,835,540
  1. Stock Market
  2. Stocks
  3. GABA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!